Study highlights multiple factors of ADHD medication use
News Jun 08, 2016
Youth who take Ritalin, Adderall or other stimulant medications for ADHD over an extended period of time early in life are no more at risk for substance abuse in later adolescence than teens without ADHD, according to a University of Michigan (U-M) study.
The findings also show that teens who start using stimulant medications for attention deficit hyperactivity disorder for a short time later in adolescence—during middle or high school—are at high risk of substance use.
See Also: Inside the adult ADHD brain
The U-M research is believed to be the first national study to compare early-use and longer-duration stimulant medication therapy with nonstimulant therapy for ADHD.
A large sample size of high school seniors also meant researchers could separate doctor-prescribed ADHD medication use by gender. The results show no gender differences in the overall associations between stimulant medication therapy for ADHD and risk of substance use, said Sean Esteban McCabe, a research professor at the U-M Institute for Research on Women and Gender.
More than 40,000 individuals from 10 cohorts nationwide between 2005 to 2014, answered questions about ADHD medication use and recent substance use as part of the Monitoring the Future study.
Among the findings:
Nearly one in eight high school seniors in the U.S. have used stimulant or nonstimulant medication therapy for ADHD.
Males are more likely to use stimulant medication therapy for ADHD, while no gender differences were found for nonstimulant medication therapy.
Given that higher substance-use behaviors are associated with later initiation of stimulant medications for ADHD during adolescence, the researchers recommend monitoring this later initiation subgroup carefully for pre-existing risk factors or the onset of substance use behaviors.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
McCabe SE et al. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study. Journal of the American Academy of Child & Adolescent Psychiatry, Published June 2016. doi: 10.1016/j.jaac.2016.03.011
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.
Researchers are One Step Closer to Developing Eye Drops to Treat Age-Related Macular DegenerationNews
Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).READ MORE
A Bad Mood May Help Your Brain With Everyday TasksNews
New research found that being in a bad mood can help some people’s executive functioning, such as their ability to focus attention, manage time and prioritize tasks.READ MORE